An observational study in Meningioma of Brain, sponsored by Central Hospital, Nancy, France. Not yet recruiting. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Central Hospital, Nancy, France · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Tumor dosimetry for meningiomas is substantially lower (7 to 8 times lower) than for neuroendocrine tumors (NETs), even though the injected activities are identical for both indications.
The hypothesis of this study is that organs at risk receive a higher absorbed dose in the case of meningiomas than with NETs.
A literature review has supported this hypothesis; therefore, it is appropriate to verify it through this retrospective study.
Tumor dosimetry for meningiomas is substantially lower (7 to 8 times lower) than for neuroendocrine tumors (NETs), even though the injected activities are identical for both indications.
The hypothesis of this study is that organs at risk receive a higher absorbed dose in the case of meningiomas than with NETs.
A literature review has supported this hypothesis; therefore, it is appropriate to verify it through this retrospective study.Thus, the aim of the study will be to determine the dosimetry of organs at risk in patients treated with Lutathera® for meningioma and for a neuroendocrine tumor (NET).
256 studies on the registry are indexed under Meningioma; 86 are open to participants now.
This study's planned enrollment of 36 is below the median of 112 across 57 observational studies indexed under Meningioma.
Browse Meningioma studies →Central Hospital, Nancy, France is the lead sponsor of 799 studies on the registry; 187 are open to participants now.
Counted across the registry records on this site, refreshed daily.
SPECT scans recorded for each patient who received at least one cycle of Lutathera® treatment for a meningioma or a NET will be analyzed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
To compare the dosimetry of organs at risk in patients treated with Lutathera® for meningioma versus neuroendocrine tumor
Calculation of dosimetry for organs at risk (kidney, spleen, liver, bone marrow) in the two patient populations treated with Lutathera®
Time frame: Day 1
To evaluate the safety monitoring of Lutathera® treatment in both populations at 3 months after the last Lutathera® cycle
Biology results
Time frame: 3 months
To evaluate the safety monitoring of Lutathera® treatment in both populations at 3 12 months after the last Lutathera® cycle
Biology results
Time frame: 12 months
No study locations are listed for this record.
Start is estimated for Nov 2026; primary completion for Feb 2027, 2 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Central Hospital, Nancy, France →